Arcutis Biotherapeutics, Inc. (ARQT) — 10-Q Filings
All 10-Q filings from Arcutis Biotherapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Arcutis Swings to Profit on Zoryve Sales Surge, Cash Dips
— Oct 28, 2025 Risk: medium
Arcutis Biotherapeutics, Inc. (ARQT) reported a significant increase in product revenue, reaching $99.219 million for the three months ended September 30, 2025, -
Arcutis's Q2 Net Loss Widens to $78.9M Amidst R&D Push
— Aug 6, 2025 Risk: high
Arcutis Biotherapeutics, Inc. reported a net loss of $78.9 million for the quarter ended June 30, 2025, a significant increase from the $65.4 million net loss i -
Arcutis Biotherapeutics Files Q1 2025 10-Q
— May 6, 2025 Risk: medium
Arcutis Biotherapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the firs -
Arcutis Biotherapeutics Files Q3 2024 10-Q
— Nov 6, 2024 Risk: medium
Arcutis Biotherapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the -
Arcutis Biotherapeutics Files Q2 2024 10-Q
— Aug 14, 2024 Risk: medium
Arcutis Biotherapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its busines - 10-Q Filing — May 14, 2024
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX